Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Interest Expenses data on file, last reported at $410.6 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 236.61% year-over-year to $410.6 million in Q1 2026; TTM through Mar 2026 was $410.6 million, a 236.61% increase from a year earlier, with the FY2025 full-year figure at $400.5 million, up 69.55% from the prior year.
• Interest Expenses for Q1 2026 stood at $410.6 million, up from $250.1 million in the prior quarter.
• Over the last five years, Interest Expenses for KYMR reached as high as $410.6 million in Q1 2026 and fell as low as $16000.0 in Q4 2024.
• Historically, Interest Expenses has averaged $122.6 million across 5 years, with a median of $125.7 million in 2023.
• Across the five-year window, Interest Expenses soared 295127.27% in 2023 and plunged 99.99% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $55000.0 in 2022, then surged by 295127.27% to $162.4 million in 2023, then plunged by 99.99% to $16000.0 in 2024, then soared by 1562743.75% to $250.1 million in 2025, then jumped by 64.2% to $410.6 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $410.6 million in Q1 2026, $250.1 million in Q3 2025, and $134.2 million in Q2 2025.